Levee Medical has announced the launch of a $10m Series B financing round to accelerate the development of its Voro Urologic Scaffold, a bioresorbable implant aimed at improving recovery outcomes after prostatectomy.

The capital will support regulatory and clinical activities, including broader clinical studies to validate the device’s safety and efficacy.

The Voro Urologic Scaffold is designed to manage bladder neck geometry and maintain urethral length during prostatectomy, which is key to preventing post-operative incontinence.

Levee Medical has also launched the ALTO observational study in the US to evaluate urinary function and quality of life post-prostatectomy.

The Urology Place in San Antonio founder Dr Naveen Kella enrolled the first patient, as part of the ALTO study.

Kella said: “We are truly excited about the progress Levee Medical is making with the Voro Urologic Scaffold.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“Their clinically robust approach to developing this innovative solution is a testament to their commitment to improving patient outcomes. The preliminary results are encouraging, and I am confident their efforts will lead to significant advancements in the treatment of post-prostatectomy urinary incontinence.”

The company has made significant strides in its ARID feasibility study, evaluating the Voro Urologic Scaffold’s safety and performance.

With 25 patients enrolled and five surgeons participating, the preliminary results are promising.

The Voro Urologic Scaffold, an absorbable device, aims to reduce the incidence of stress urinary incontinence significantly, offering a potential solution for patients undergoing radical prostatectomy.

In 2022, Levee Medical closed $6.6m in an initial oversubscribed series A financing round to fund the development of the Voro Urologic Scaffold.